Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

uniQure N.V.

Fully enroll the ten-patient first cohort in the AMT-130 Phase I/II trial

Delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
1 Mar 2021
Due
30 Jun 2021
Delivered
5 Apr 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“The ten-patient cohort is on track to be fully enrolled by mid-2021.”

What we found

Evidence strength A What the grades mean

Filings state that enrollment of all ten patients in the first dose cohort was completed and announced on April 5, 2021, before the mid-2021 deadline. One 8-K describes the completion as announced in May 2021, which is also before the deadline.

  • A
    uniQure N.V. 8-K filed 2021-07-27 Regulatory filing · published 27 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “In May 2021, the Company announced the completion of patient enrollment of the first dose cohort of ten patients in its ongoing Phase I/II study of AMT-130 in Huntington's disease.” ✓ confirmed on the page
  • A
    uniQure N.V. 10-Q filed 2021-07-26 Regulatory filing · published 26 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “On April 5, 2021 we announced the completion of enrollment of all ten patients in the first dose cohort of our Phase Ib/II clinical trial of AMT-130.” ✓ confirmed on the page
  • A
    uniQure N.V. 10-Q filed 2021-10-25 Regulatory filing · published 25 Oct 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “On April 5, 2021, we announced the completion of enrollment of all 10 patients in the first dose cohort of our Phase I/II clinical trial of AMT-130.” ✓ confirmed on the page

Checked 26 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Fully
Deliverable
Full enrollment of ten-patient cohort in AMT-130 trial
Language
Firm (“will”, “on track to”)
In the company’s control
High
Specificity
Medium

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-QURE-024800 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.